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AbstrAct
Objectives Mortality due to liver disease (of which 
cirrhosis is the end stage) is increasing more than any 
other chronic condition in the UK. This study aims to 
demonstrate that (1) exclusive reliance on mortality rates 
may not reveal the true burden of liver cirrhosis, and (2) 
diverse use of diagnostic coding may produce misleading 
estimates.
Design Observational study.
Setting The Office for National Statistics death registry 
was interrogated to investigate liver cirrhosis mortality 
trends in England and Wales from 1968 to 2011.
Main outcome Standardised mortality trends according 
to three different definitions of liver cirrhosis based on the 
specificity of diagnostic codes were calculated: 1 (chronic 
liver diseases), 2 (alcoholic and unspecified cirrhosis only) 
and 3 (cirrhosis as end-stage liver disease). The mortality 
trends were compared with incidence rates established in 
a previous population-based study (based on definition 3), 
from 1998 to 2009, to investigate discrepancies between 
these two measures.
Results Over the study period, the overall standardised 
liver cirrhosis mortality rates were 8.8, 5,1 and 5.4 
per 100 000 person-years for definitions 1, 2 and 3, 
respectively. The mortality rates for definition 3 in 1998 
and 2009 were 6.2 and 5.9 per 100 000 person-years, 
respectively; while the equivalent incidence rates were 
at least threefold and sixfold higher: 23.4 and 35.9 per 
100 000 person-years, respectively. This discrepancy 
between incidence and mortality rates was also at least 
threefold in men and women separately and across age 
groups.
Conclusion Mortality rates underestimated the 
incidence of liver cirrhosis by at least threefold between 
1998 and 2009 and varied with differing definitions of 
disease. Mortality data should not be used exclusively 
as an indicator for the occurrence of liver cirrhosis in 
the population. Routinely collected healthcare data are 
available to measure occurrence of this disease. Careful 
consideration should be taken when selecting diagnostic 
codes for cirrhosis.
IntroductIon
Liver disease, of which liver cirrhosis is 
the end stage, constitutes the third most 
common cause of premature death in the 
UK.1 According to the UK’s current chief 
medical officer (CMO), the rate of increase 
in premature mortality from liver disease 
and from cirrhosis is substantially higher 
in the UK than other countries in Western 
Europe.2 Further, cirrhosis per se has recently 
been reported to be increasing in the UK at a 
faster rate than the top four most-commonly 
diagnosed cancers (lung, breast, bowel and 
prostate).3 The main reasons for the rise in 
cirrhosis are probably parallel increases in 
alcohol consumption and obesity.1 4 In the 
UK, alcohol consumption per person across 
the population has more than doubled in 
the last half-century and one in four adults 
are now considered to be obese.5 6 These are 
preventable causes and interventions such as 
minimum pricing for alcoholic drinks, and 
campaigns for healthier lifestyles have been 
considered as part of a strategy to reduce liver 
disease.7 8
Despite its 5-year mortality being equiv-
alent to that seen in colon cancer, and in 
contrast to the monitoring of new cancer 
diagnoses, there is no mandatory registration 
of cirrhosis cases in the UK or elsewhere in 
the world.9 Estimates of the occurrence of 
cirrhosis, and consequently the assessment 
of success or failure of primary interven-
tions, have therefore been primarily drawn 
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Research
Strengths and limitations of this study
 ► First study to quantify the difference in liver cirrhosis 
mortality rates based on different definitions of 
disease
 ► First study to demonstrate that overall mortality 
rates underestimate the incidence of liver cirrhosis 
by at least threefold
 ► A key strength of the study is the large number of 
registered deaths and the long period of time that 
the data were obtained over.
 ► A potential limitation of death registry data is the 
change in coding practice over time.
 ► The Office for National Statistics data cover deaths 
in England and Wales combined, whereas the 
incidence data are based solely on English general 
practices.
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from death registry data.1 2 This methodology is likely to 
mask the true incidence of cirrhosis. First, not everyone 
with cirrhosis dies directly due to the disease, and our 
recent population-based study estimated that only 32% 
of deaths in people with cirrhosis had a cirrhosis-related 
code anywhere on their death certificate.10 Second, 
there is a time-lag between diagnosis and death. Hospi-
tal-based studies have reported survival estimates at 1 year 
of around 65%.11 12 Those who do not die immediately 
after diagnosis, and those who do not die directly from 
the disease, will not be accounted for by reliance on the 
death registry.
Establishing accurate estimates of cirrhosis is further 
compounded by the fact that there is no clear boundary 
between liver disease and cirrhosis. There are a myriad 
of liver diseases and for each one patients progress to 
cirrhosis at different rates, if at all.13 Previous authors of 
well-cited papers have used a range of codes representing 
different liver diseases when reporting mortality due to 
‘liver cirrhosis’.11 12 14 Subsequently it is often not possible 
to determine whether authors are truly examining liver 
disease or cirrhosis per se.
In the UK, as in many Northern European countries, 
patients with suspected liver cirrhosis may be diagnosed 
by their primary care physician, or more commonly are 
referred to a secondary care specialist who will then 
pass on information to the primary care physician. Our 
research group has therefore used linked primary and 
secondary routine healthcare databases to capture the 
incidence of cirrhosis as comprehensively as possible.3 
Given the dependence of health service planning on 
accurate knowledge of occurrence of disease, we sought 
to use routinely available data to (1) examine how 
cirrhosis mortality rates may differ according to the 
range of specificity of diagnostic codes used within the 
hepatology community and (2) quantify the difference 
between cirrhosis mortality rates (from death registry 
data) and cirrhosis incidence rates (previously estab-
lished) from linked routine healthcare databases) based 
on the same definition of disease and over the same time 
period.
Methods
data sources
We obtained mortality data from the Office for National 
Statistics (ONS) website (https://www. ons. gov. uk). These 
data are derived from registered death certificates and 
consist of counts of death by underlying cause (based on 
the International Classification of Disease (ICD)15) year 
of death, 5-year age group and sex for England and Wales 
from 1968 to 2011. Population data for the respective 
years were also obtained from the ONS website stratified 
by 5-year age group and sex. We used the linked Clinical 
Practice Research Datalink (CPRD) and English Hospital 
Episodes Statistics (HES) to conduct a cohort study iden-
tify incident diagnoses of cirrhosis between 1998 and 
2009 (n=5118). The diagnoses in the CPRD are made by 
histological examination and/or characteristic clinical 
signs of advanced liver disease.3
definitions of cirrhosis
We used three definitions of cirrhosis according to the 
specificity of ICD diagnostic coding.
Definition 1
This code list was developed by Leon and McCambridge14 
for international comparisons and has been selected as it 
is a relatively broad definition of cirrhosis and includes 
other chronic liver disease (eg, alcoholic liver disease 
and chronic hepatitis) and has been used widely by other 
authors.16
Definition 2
This is a restrictive definition used by Jepsen et al,17 
including only alcoholic and unspecified cirrhosis of the 
liver.
Definition 3
This code list reflects cirrhosis as the end stage of liver 
disease and includes codes for portal hypertension and 
oesophageal varices which are not included in the above 
definitions. This code list is the same definition our 
group has used previously to define a cohort of people 
with an incident diagnosis of cirrhosis in England using 
the linked CPRD and HES.3
To provide a context, we combined all liver diseases 
according to ICD version 10 chapter ‘Diseases of the 
Liver’ (K70–K77) and refer to this this category as ‘liver 
disease’. During the calendar period, considered three 
different revisions of the ICD were used and mapping 
across these three versions are shown in online supple-
mentary tables 1 and 2.15 18 19
statistical analysis
Mortality rates
Age at death was categorised from the age of 15 years in 
three groups (<45, 45–64 and ≥65 years). We determined 
crude mortality rates per 100 000 person-years from 
1968 to 2011 for liver disease and all three definitions of 
cirrhosis. We calculated age stratum and sex stratum-spe-
cific cirrhosis mortality rates and applied these to the 2011 
population to generate annual standardised mortality 
rates. Negative binomial regression modelling was used 
to estimate mortality rate ratios with adjustment for age 
and sex. We determined average annual increase.
Incidence rates
Determining the incidence of cirrhosis (using definition 
3) has been described elsewhere.3 In brief, we defined a 
cohort of incident diagnoses from the linked CPRD and 
English HES data from 1998 to 2009 for adults from the 
age of 18 years onwards. Estimates of incidence from the 
study have been standardised to the 2011 population 
and used in this current paper to make a direct compar-
ison with standardised mortality rates over the same time 
period and using the same definition of disease.
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Figure 1 Standardised* mortality rates for England and Wales, 1968–2011, for liver disease† and different definitions‡ of 
cirrhosis. Standardised* incidence rates for definition 3, from 1998 to 2009. *Age and sex standardised to the 2011 population 
in England and Wales. †ICD-8, ICD-9 and ICD-10 codes listed for each definition in online supplementary tables 1 and 2. 
‡Liver disease defined as ICD-10 codes for ‘Diseases of the Liver’ K70–K77 (or equivalent ICD-8 and ICD-9 codes, see online 
supplementary tables 1 and 2). ICD-8–10, International Classification of Diseases Eighth, Ninth and Tenth Revision.
results
standardised mortality rates
The overall standardised mortality rates for definitions 
1 to 3 of cirrhosis over the study period were 8.8 (95% 
CI 8.8 to 8.8), 5.4 (95% CI 5.4 to 5.5) and 5.1 (95% CI 
5.0 to 5.1) per 100 000 person-years, respectively. Figure 1 
displays the standardised mortality trends from 1968 to 
2011 for all definitions. There was only a marginal differ-
ence in absolute and relative terms between liver diseases 
combined and definition 1, and similarly, only a marginal 
difference between definitions 2 and 3.
Between 1979 (the introduction of ICD Ninth Revision 
(9)) and 2001 (the introduction of ICD Tenth Revision 
(10)), the average annual relative increase in mortality 
from cirrhosis was 1.04 (95% CI 1.03 to 1.04), 1.01 
(95% CI 1.01 to 1.01) and 1.01 (95% CI 1.01 to 1.02) 
for definitions 1, 2 and 3 respectively. From 2001 onwards 
the increase was smaller for all definitions: 1.00 (95% CI 
1.00 to 1.01), 1.00 (95% CI 0.99 to 1.00) and 0.99 (95% CI 
0.99 to 1.00), respectively.
From 1992 to 2008, the absolute difference in rates 
between those of definition 1 and definition 2 diverged 
further with time. For example, the absolute rates for 
definition 1 in 1992, 1996 and 2008 were 7.8, 9.4 and 14.6 
per 100 000 person-years; the equivalent for definitions 2 
and 3 were 4.8, 5.5 and 5.8 and 5.5, 5.7 and 5.8, respec-
tively.
change in cause of death over time
To explore possible reasons for the divergence in deaths 
between the different definitions of disease, from 1992 
and 2008, we have presented the distribution of causes 
of death in 1992 and 2008 per definition (table 1). We 
have not displayed the distribution for definition 2 as it is 
similar to that of definition 3.
In 1992, the percentage of deaths attributed to alcoholic 
liver damage (ICD-9 5713), which is included in defini-
tion 1 but not in definition 3, was 21.2%. This increased 
to 40.1% in 2008 (ICD-10 K70.9). During the same time 
frame, the percentage of deaths due to alcoholic cirrhosis 
(ICD-9 5712) decreased from 24.6% to 15.7%. In contrast, 
the distribution of causes of death of definition 3 did not 
change that dramatically. For example, 35.4% of deaths 
in 1992 were due to alcoholic cirrhosis of the liver (ICD-9 
5712) and the equivalent proportion in 2008 was 39.4% 
(ICD-10 K70.3). Similarly, the proportion of deaths due 
to cirrhosis without mention of alcohol was 52.2% in 1992 
(ICD-9 5715) and 57.5% in 2008 (ICD-10 K74.6).
comparison between mortality and incidence rates
In a previous study, we determined the incidence of 
cirrhosis in England during the period 1998 to 2009 
using definition 3 of cirrhosis.3 These rates have been 
standardised to the 2011 population and inserted into 
figure 1. Specifically, the standardised incidence rates were 
23.4 and 35.9 per 100 000 person-years in 1998 and 2009, 
respectively. This is in sharp contrast to the standardised 
mortality rates of 6.2 and 5.9 per 100 000 person-years 
in 1998 and 2009, respectively (in England and Wales). 
The overall rate of change between 1998 and 2009 was 
50.6% for incidence, whereas mortality rates decreased 
by 2.5% over the same time period. The mortality rates 
according to definition 1 were also substantially less than 
the estimates of incidence; 11.1 and 13.8 per 100 000 
person-years in 1998 and 2009, respectively, equating to a 
rate of change of only 28.9% across the period (figure 1).
For both sexes, the standardised incidence rates 
were between threefold and sixfold that of mortality 
(definition 3) in all age groups, across the study 
period (figures 2 and 3). The incidence rates were also 
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Table 1 Distribution of causes of death for liver cirrhosis definitions 1 and 3 in 1992 and 2008, n (%)
ICD description
ICD-9 
code
ICD-10 
code
Liver cirrhosis–
definition 1
Liver cirrhosis–
definition 3
1992 2008 1992 2008
n=3050 n=6469 n=2118 n=2584
Alcoholic fatty liver 5710 K70.0 34 (1.1) 229 (3.5) – –
Acute alcoholic hepatitis 5711 K70.1 77 (2.5) 148 (2.3) – –
Alcoholic cirrhosis of liver 5712 K70.3 749 (24.6)
1018 
(15.7) 749 (35.4)
1018 
(39.4)
Alcoholic liver damage, unspecified 5713 K70.9 647 (21.2)
2594 
(40.1) – –
Chronic hepatitis 5714 K73.9 95 (3.1) 6 (0.1) – –
Cirrhosis of liver without mention of alcohol/other 
and unspecified cirrhosis of liver 5715 K74.6 1106 (36.3) 1485 (23) 1106 (52.2)
1485 
(57.5)
Biliary cirrhosis 5716 K74.5 206 (6.8) 9 (0.1) 206 (9.7) 9 (0.3)
Other chronic non-alcoholic liver disease 5718 52 (1.7) –
Unspecified chronic liver disease without mention 
of alcohol 5719 84 (2.8) –
Oesophageal varices with bleeding 4560 I85.0 – – 42 (2.0) 35 (1.4)
Oesophageal varices without bleeding 4561 I85.9 – – 15 (0.7) 6 (0.2)
Alcoholic fibrosis and sclerosis of liver K70.2 – 1 (0.02) – –
Alcoholic hepatic failure K70.4 – 774 (12) – –
Chronic hepatic failure K72.1 – – – 10 (0.4)
Chronic active hepatitis, not elsewhere classified K73.2 – 58 (0.9) – –
Hepatic fibrosis K74.0 – 5 (0.08) – –
Hepatic sclerosis K74.1 – 1 (0.02) – –
Primary biliary cirrhosis K74.3 – 137 (2.1) – –
Secondary biliary cirrhosis K74.4 – <5 (0.1) – <5 (0.2)
Other and unspecified cirrhosis of liver K74.6 – – – –
Portal hypertension K76.6 – – – 17 (0.7)
ICD-9, International Classification of Diseases Ninth Revision; ICD-10, ICD Tenth Revision.
substantially higher than mortality rates based on defini-
tion 1, for both men and women and across all age groups.
dIscussIon
Main findings
We found that both the absolute and relative cirrhosis 
mortality rates varied with differing disease definition. 
The overall age-standardised mortality rates during 1968 
to 2011 were 8.8, 5.1 and 5.4 per 100 000 person-years 
for definitions 1 to 3, respectively. Careful consideration 
should be taken when selecting diagnostic codes for 
cirrhosis so that they are in line with the research ques-
tion and research wastage is minimised. Further, using 
different routinely available clinical datasets, we have 
previously demonstrated that between 1998 and 2009, 
the incidence of cirrhosis increased by 50.6%, which is in 
contrast to a decrease in mortality from cirrhosis of 2.5% 
based on the same definition of disease.3 Cirrhosis inci-
dence rates were consistently higher than mortality rates, 
at least threefold between 1998 and 2009, independent of 
age and sex. Mortality rates should therefore not be used 
alone to monitor the occurrence of cirrhosis; alternative 
sources of routinely collected data should be considered.
strengths and limitations
This is the first study to quantify the difference in cirrhosis 
mortality rates by differing definitions of disease and the 
first to compare cirrhosis mortality and incidence rates 
using the same definition of disease. Key strengths of the 
study are its external validity, the large number of regis-
tered deaths and the long period of time that the data 
were obtained over. The latter meant that we were able to 
report trends of mortality rates for a period of more than 
40 years. A potential limitation of death registry data is 
the change in coding practice over time, known as coding 
phenomenon. The change in rate of specific causes of 
death over time could be due to the use of different ICD 
versions throughout the study period rather than a true 
change. For example, the sharp increase in the number of 
liver disease deaths (definition) 1 after 1979 when ICD-9 
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Figure 2 Standardised* mortality and incidence† rates by age group in men, according to cirrhosis definitions 1 and 3‡. *Age 
and sex standardised to the 2011 population in England and Wales. †Incidence estimates taken from Ratib et al.3 ‡ICD-8, ICD-
9 and ICD-10 codes listed for each definition in online supplementary tables 1 and 2. ICD-8–10, International Classification of 
Diseases Eighth, Ninth and Tenth Revision.
Figure 3 Standardised* mortality and incidence† rates by age group in women, according to liver cirrhosis definitions 1 and 
3‡. *Age and sex standardised to the 2011 population in England and Wales. †Incidence estimates taken from Ratib et al.3 
‡ICD-8, ICD-9 and ICD-10 codes listed for each definition in online supplementary tables 1 and 2. ICD-8–10, International 
Classification of Diseases Eighth, Ninth and Tenth Revision.
came into use, followed by a reduction in the rate of 
change from 2001 onwards when ICD-10 came into place. 
This phenomenon has been reported by others.20 Coding 
phenomenon also occurs when doctors change the way 
they select codes on death certificates. For example, over 
time doctors may be more likely to use codes for alcoholic 
liver disease even in the presence of alcoholic cirrhosis. 
This may explain the increase in deaths coded as alco-
holic liver damage in contrast to the fall in deaths coded 
for alcoholic cirrhosis, which we report in this study. 
Despite the potential changes in coding practice over 
time, mortality rates using the broadest definition of liver 
disease are still dramatically lower than the incidence 
rates of cirrhosis reported using a relatively restricted 
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definition. Finally, the ONS data cover deaths in England 
and Wales combined, whereas the incidence data are 
based solely on English general practices so we are not 
exactly comparing like with like. However, given similar 
liver disease mortality in England and Wales,21 if death 
registry data for England only were available and had 
been used, the discrepancy between mortality and inci-
dence would highly unlikely be less than that which we 
report and our conclusions would remain the same.
Implications
Our findings provide evidence that using mortality data 
alone to measure the occurrence of cirrhosis could have 
major implications on healthcare planning. Given the 
sharp rise in cirrhosis incidence in the last decade that is 
not visible from mortality statistics, the National Health 
Service may well be under resourced and unable to cope 
with future demand on hepatology clinics. Mortality 
and incidence are two very different measures of disease 
burden. If only cirrhosis which leads to death from 
cirrhosis is of importance to clinicians and policy-makers, 
then measuring mortality is indeed the more appro-
priate measure. However if we are truly concerned with 
measuring the occurrence of cirrhosis and/or the impact 
of public health intervention strategies, then incidence 
rates are crucial. When establishing the success of public 
health interventions aimed at reducing new disease, such 
as alcohol policies and healthy eating campaigns, it is 
essential to set targets for incidence to determine if these 
sorts of interventions have been effective or not. Evalua-
tion of such interventions needs to account for the long 
sojourn between disease onset and fibrosis/cirrhosis, 
which can take between 10 and 30 years.22 Mortality is 
even further away, therefore even less relevant a measure 
than incidence. The study by Leon and McCambridge14 
(definition 1) used mortality rates as they were believed 
to be important indicators of population levels of alcohol 
harm. However, our findings suggest that the use of inci-
dence rates would have been more indicative. Finally, 
differences in incidence and mortality could be partially 
due to improvement in treatment and care of chronic liver 
disease, if anything this means that with improving treat-
ment mortality becomes an even worse proxy measure of 
burden. One recommendation for future work, from this 
study, is to measure the incidence of cirrhosis by using 
routinely collected healthcare data often known as ‘Big 
Data’. Such data are becoming increasingly familiar and 
accepted in hepatology with, for example, the recent 
Lancet Commission recommending non-alcoholic fatty 
liver disease prevalence be measured by establishing a 
cohort from primary care data.1 The strengths of using 
routinely collected data are from methodological and 
cost-effectiveness perspectives. First, the recent linkage of 
primary care and secondary care allows a representative 
cohort of patients covering the full spectrum of disease 
to be identified, representative of the English popula-
tion.3 23Second, accessing large amounts of routinely 
collected data for chronic diseases is substantially cheaper 
than establishing a bespoke prospective cohort of patients 
and following them potentially for several decades. 
Similar discrepancies between mortality and incidence 
figures have been shown in other diseases for which there 
is no mandatory recording such as idiopathic pulmonary 
fibrosis.24 Routinely collected data may be appropriate to 
measure the incidence of this condition too.
The second implication of our findings is the neces-
sity of careful consideration of disease definition. We 
have shown that the inclusion of patients who died 
from chronic liver diseases introduced an overestimate 
of cirrhosis mortality rates, by about 60%, comparing 
definitions 1 and 3 (8.8 per 100 000 vs 5.4, respectively). 
Definition 1 included codes related to alcoholic liver 
disease such as alcoholic fatty liver disease (K70.0) and 
alcohol liver disease (K70.9) (the latter contributed 40% 
of ‘definition 1’ deaths in 2008), as well as autoimmune 
diseases, which were not included in definition 3. With 
respect to alcoholic liver disease, some patients with this 
condition can fluctuate between alcoholic fatty liver and 
alcoholic hepatitis and not actually completely progress 
to cirrhosis, and if they stop drinking, the architecture 
of their liver may return to normal.13 Consequently, on 
one hand, it may be misleading to include codes such as 
alcoholic fatty liver disease (K70.0), alcoholic hepatitis 
(K70.1) and alcohol liver disease (K70.9) when intending 
to measure deaths due to cirrhosis. Conversely, one could 
argue that as these diagnostic codes represent diseases 
which could be a precursor to cirrhosis, they could actu-
ally reflect a poor specification of decompensated disease 
and hence cirrhosis. For example, this current study has 
shown that a particular difference between definitions 1 
and 3 in the rate of change cirrhosis between 1992 and 
2008 may have been mediated through an increase in 
deaths coded as the broader term ‘alcoholic liver disease’ 
with a concomitant decline in the number of deaths 
coded as the more specific ‘alcoholic cirrhosis’. One 
cannot disprove the possibility of an artefactual differ-
ence due to clinicians’ certification practice rather than 
a true increase in alcoholic liver disease compared with 
alcoholic cirrhosis. Therefore, it may indeed be appro-
priate to use broader codes like alcoholic liver disease to 
capture patients with cirrhosis who may not have been 
certified as dying from cirrhosis per se. The key point is 
that code lists should reflect the precise research ques-
tion that is being posed, otherwise results are misleading. 
Future research should take this finding into account. 
We acknowledge that specific ICD-10 codes for chronic 
viral hepatitis such as chronic hepatitis B (B18.1) and 
chronic hepatitis C (B18.2) have not been considered by 
researchers in the field. Inclusion of these codes could 
also be considered when developing a broad definition 
of cirrhosis.
conclusion
This study has highlighted that reliance on mortality 
data alone may lead to an underestimate of the occur-
rence of cirrhosis, and indeed liver disease in general. 
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Consequently the occurrence of liver disease in England 
is likely to be considerably greater than that which others 
report, including the current UK CMO.1 2 25 26 Alternative 
sources of routinely collected data should be considered 
as a matter of urgency and appropriate definitions of 
disease employed. Accurate monitoring of the incidence 
of cirrhosis will allow the optimisation of limited health-
care services and provide appropriate baseline figures 
from which to evaluate intervention, particularly those 
implemented at population level.
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